Concepedia

Author

Oleksandr Bilchenko

Steno Diabetes CentersORCID

Also Known As

A Bilchenko, A V Bil'chenko, A V Bilchenko, A V Erbasskaia, A. Bilchenko, A. V. Bilchenko, A.V. Bilchenko, Aleksandr V Bilchenko, Aleksandr V. Bilchenko, Hans Furuland

66

Publications

625

Citations

5

H-Index

0

Concepts

All Affiliations

Steno Diabetes CentersThe University of Texas Southwestern Medical CenterUniversity College LondonStanford UniversityAstraZeneca (Sweden)
OB

About

Oleksandr Bilchenko is an author at Steno Diabetes Centers.

Oleksandr Bilchenko

×

3

Publications

390

Citations

3

H-Index

YearCitations

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

David C. Wheeler, Bergur V. Stefánsson, Oleksandr Bilchenko,

Nephrology Dialysis Transplantation

2020

180

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

Hiddo J.L. Heerspink, C. David Sjöström, Niels Jongs,

European Heart Journal

2021

118

A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

Hiddo J.L. Heerspink, David Z.I. Cherney, Douwe Postmus,

Kidney International

2021

92

Page 1